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Long-term IL-33–producing
epithelial progenitor cells in
chronic obstructive lung disease
Derek E. Byers,1 Jennifer Alexander-Brett,1 Anand C. Patel,1,2 Eugene Agapov,1
Geoffrey Dang-Vu,1 Xiaohua Jin,1 Kangyun Wu,1 Yingjian You,1 Yael Alevy,1
Jean-Philippe Girard,3 Thaddeus S. Stappenbeck,4 G. Alexander Patterson,5
Richard A. Pierce,1 Steven L. Brody,1 and Michael J. Holtzman1,6
1Department

of Medicine and 2Department of Pediatrics, Washington University School of Medicine, Saint Louis, Missouri, USA. 3Institute of Pharmacology
and Structural Biology, National Center of Scientific Research, University of Toulouse, Toulouse France. 4Department of Pathology and Immunology,
5Department of Surgery, and 6Department of Cell Biology, Washington University School of Medicine, Saint Louis, Missouri, USA.

Chronic obstructive lung disease is characterized by persistent abnormalities in epithelial and immune cell
function that are driven, at least in part, by infection. Analysis of parainfluenza virus infection in mice revealed
an unexpected role for innate immune cells in IL-13–dependent chronic lung disease, but the upstream driver
for the immune axis in this model and in humans with similar disease was undefined. We demonstrate here
that lung levels of IL-33 are selectively increased in postviral mice with chronic obstructive lung disease and
in humans with very severe chronic obstructive pulmonary disease (COPD). In the mouse model, IL-33/IL-33
receptor signaling was required for Il13 and mucin gene expression, and Il33 gene expression was localized
to a virus-induced subset of airway serous cells and a constitutive subset of alveolar type 2 cells that are both
linked conventionally to progenitor function. In humans with COPD, IL33 gene expression was also associated
with IL13 and mucin gene expression, and IL33 induction was traceable to a subset of airway basal cells with
increased capacities for pluripotency and ATP-regulated release of IL-33. Together, these findings provide a
paradigm for the role of the innate immune system in chronic disease based on the influence of long-term
epithelial progenitor cells programmed for excess IL-33 production.
Introduction
It is widely believed that the innate immune system mediates
the acute response to an infectious agent, but recent work shows
that this response can also translate acute infection into chronic
inflammatory disease. This paradigm may apply particularly to
the chronic airway disease found in chronic obstructive pulmonary disease (COPD) (1). In this case, bacterial infection of the
lower airways is often associated with COPD exacerbation and
progression (2), but more sensitive PCR-based technology detects
respiratory viruses in the airway with high frequency as well (3–7).
Moreover, viral challenge shows that viral infection alone is sufficient to induce COPD exacerbation and to lead to secondary bacterial infection with exacerbation (8, 9). Despite these associations,
a primary cause-and-effect relationship between viral infection
and the pathogenesis of COPD remains to be fully established. In
that regard, the relatively transient nature of most respiratory viral
infections and the relatively permanent nature of chronic inflammatory lung disease remain difficult to reconcile. This discrepancy
appears even more difficult to resolve for inflammation, due to an
innate immune response that is conventionally viewed as built for
short-term, rather than long-term, activation.
To better understand the connections among viral infection,
immune response, and chronic obstructive lung disease, we develAuthorship note: Derek E. Byers and Jennifer Alexander-Brett contributed equally to
this work.
Conflict of interest: Michael J. Holtzman is the principal investigator for grants to
Washington University from Hoffman-La Roche and Forest Labs.
Citation for this article: J Clin Invest. 2013;123(9):3967–3982. doi:10.1172/JCI65570.

oped a mouse model of these events and a corresponding system
for analysis of COPD patients, from which whole lung explants are
available for study. Our initial work on the mouse model showed
that a single infection with a mouse parainfluenza virus known as
Sendai virus (SeV) leads to long-term airway inflammation (10).
Analysis of this model uncovered an innate immune axis involving
semi-invariant NKT cells and alternatively activated (M2) macrophages that resulted in IL-13 expression and consequent airway
hyperreactivity (monitored by methacholine-induced bronchoconstriction) and mucus overproduction (signified by mucin MUC5AC
expression) (11). We also found initial evidence of IL-13 expression along with M2 monocyte/macrophage accumulation and
MUC5AC production in the lungs of patients with severe COPD
(11–13). These results identified an innate immune response to
translate viral infection into chronic obstructive lung disease, but
still did not explain how the response could be perpetuated.
To address this issue, we reasoned that persistent upstream events
might continually drive the innate immune axis we had identified.
In that regard, studies of other experimental models have revealed
that the innate immune system can control IL-13 production and
the associated Th2 response with at least 3 key mediators: TSLP,
IL-25, and IL-33 (14, 15). Each of these 3 cytokines has been reported to be the product of both parenchymal cells (especially at the
epithelial or endothelial surface) and various immune cells, and
each has been shown to be necessary for the development of Th2
inflammation and airway hyperreactivity in experimental models
of asthma using allergen challenge (16–21). Considerably less is
known about these cytokines during the innate immune response
to respiratory viral infection and any associated chronic lung dis-
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Figure 1
Selective increase in Il33 gene expression in a postviral mouse model of chronic lung disease. (A) Gene expression microarray analysis of mRNA
from lungs of mice at dpi 49 with SeV (1 × 105 pfu) or SeV-UV. The plot depicts quantile-normalized log2-transformed gene expression values.
Each symbol represents the expression value for an individual gene. The 20 genes with the greatest relative change, additional relevant genes,
and those encoding ILs and IL receptors are annotated. Diagonal lines represent line of equality (solid line) and 2-fold expression difference
(dashed line). Significant differences for SeV versus SeV-UV values (determined as described in Methods) are indicated by colored symbols for
annotated genes. (B) Expression levels of Il33, Il25, and Tslp mRNA in whole lung tissues from mice with SeV or SeV-UV at dpi 49. (C) Levels of
IL-33, determined by ELISA, using lung lysates from dpi 49. (D) Levels of Il33, Il13, Muc5ac, and Chi3l3 mRNA at the indicated dpi. (B–D) Values
represent mean ± SEM (n = 5–7 per condition). *P < 0.05 versus corresponding SeV-UV.

ease. Initial work showed that IL-33 receptor (also known as ST2)
signaling promoted the Th2 response to respiratory syncytial
virus (RSV) in RSV-G–primed mice (22), but implications for host
defense or postviral disease are difficult to discern, since the replication of a human-specific pathogen such as RSV is limited in mice,
and any effects on airway inflammation and dysfunction are shortlived (23). A more recent report showed that IL-33 production from
lung macrophages was required for airway hyperreactivity after
infection with influenza A virus (IAV) (24). However, similar to the
RSV model, this study also concentrated on the early response to
virus, in this case at only 1 day after infection. This outcome may
not fit with the full spectrum of clinical experience in humans, in
3968

which inflammatory airway disease might last for weeks and might
further progress for many years. Moreover, there is little extension
of these findings in mice to humans. There are preliminary reports
of increased TSLP in COPD (25) and TSLP, IL-25, and IL-33 in asthma (26–29), but the mechanism for increased expression remains
uncertain, particularly as it might relate to viral infection. Moreover, there is little information on the effect of these pathways on
airway mucus production, despite the primary role of this endpoint
in the morbidity and mortality of obstructive lung disease (30–33).
In the present study, we examined the potential role of TSLP,
IL-25, and IL-33 in the postviral mouse model and in patients with
very severe COPD. In both systems, we found that IL-33 was the
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primary candidate for regulating events upstream to IL-13 production. Moreover, IL-33 production localized to types of lung epithelial cells linked to progenitor function in both mice and humans
(34–36). Indeed, tools for basal cell isolation allowed us to define
a subset of this population as a potentially renewable source of
excess IL-33 in COPD. Together, the findings help to reconcile the
acute and transient nature of the antiviral response of the innate
immune system, including a new epithelial progenitor cell component, with the persistent and sometimes-progressive nature of
chronic obstructive lung disease.
Results
Increased IL-33 in the mouse model. We analyzed whole genome expression in lungs from mice inoculated with SeV versus UV-inactivated
SeV (SeV-UV) and obtained the expected increase in expression of
genes for mucus production (e.g., Clca3 and Muc5ac) and M2 differentiation (e.g., Alox12e, Arg1, Chit3l3/4, Mmp12, and Retnla) at 49 days
postinoculation (dpi 49) (Figure 1A and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/
JCI65570DS1). In addition, we found that Il33 gene expression was
the most upregulated of all IL-encoding genes represented on the
microarray (Figure 1A and Supplemental Table 1). In contrast, there
was no significant upregulation of either Il25 or Tslp mRNA level
at SeV dpi 49. Selective induction of Il33 mRNA was confirmed by
specific real-time PCR assay of lung mRNA from mice at SeV dpi
49 compared with mice inoculated with SeV-UV or PBS (Figure 1B
and data not shown). Moreover, postviral induction of Il33 mRNA
was accompanied by a corresponding increase in the level of IL-33
protein in the lung at SeV dpi 49 (Figure 1C). In contrast to the pattern for induction of IL-33, the level of Il25 mRNA was again not
significantly different, while the level of Tslp mRNA was significantly
decreased, at SeV dpi 49 (Figure 1B). The time course for Il33 gene
expression developed in concert with Il13 gene expression, with an
early increase at SeV dpi 3 and a later increase at dpi 21 that became
maximal at dpi 49 (Figure 1D). This late increase in Il33 and Il13 gene
expression corresponded to increases in IL-13 target gene expression,
including Muc5ac (representative of mucus production) and Chi3l3
(representative of M2 differentiation) (Figure 1D). This time course
of gene expression was not found for Il25 or Tslp (Supplemental Figure 1). Together, these findings suggested linkage between IL-33
expression and IL-13–dependent lung disease after viral infection.
Requirement for IL-33 in the mouse model. We next used 3 approaches to determine whether IL-33/IL-33 receptor signaling is required
for IL-13 production and consequent chronic lung disease in the
postviral mouse model. In the first approach, we blocked signaling with a mAb directed against IL-1 receptor–like 1 (IL1RL1), the
ligand-binding component of the heterodimeric IL-33 receptor.
We observed a marked decrease in the levels of IL-13+ immune
cells and MUC5AC+PAS+ mucous cells in the lung at SeV dpi 49
in mice treated with anti-IL1RL1 mAb compared with untreated
or control IgG1 mAb–treated mice (Figure 2A). These inhibitory
effects translated into a corresponding decrease in induction of
Il13 and Muc5ac gene expression as well as MUC5AC+ mucous cells
at SeV dpi 49 (Figure 2, B and C). In addition, we also found significant decreases in the levels of Arg1 and Chi3l3 mRNA in the lung
at SeV dpi 49 in mice treated with anti-IL1RL1 mAb compared
with control mice (Figure 2D). These results were consistent with a
decrease in M2 differentiation during postviral disease. Treatment
with anti-IL1RL1 mAb was begun on SeV dpi 12, so the effect cannot be attributed to an action on the acute inflammation and/or

viral replication found after SeV inoculation, which subside by
this time (11). In contrast to the decrease in IL-13 production, we
found no significant changes in Il33 or Il1rl1 mRNA levels during
anti–IL-33 mAb treatment (Figure 2E). We also observed no gross
difference in the degree of immune cell infiltration in anti-IL1RL1
mAb–treated mice, similar to previous results obtained with blockade of IL-13/IL-13 receptor signaling (11).
In the second approach, we examined the effect of interrupting
IL-33/IL-33 receptor signaling using Il1rl1–/– mice. We detected no
difference in acute illness (as assessed by weight loss, viral level, and
tissue inflammatory response) between Il1rl1–/– and WT mice after
SeV inoculation (Figure 3, A–C). However, we again observed significant blockade of the expected increases in mucus production,
IL-13 and MUC5AC immunostaining, and Il13, Muc5ac, and Arg1
mRNA at SeV dpi 49 in Il1rl1–/– versus WT mice (Figure 3, D–F).
The Il1rl1–/– mice also afforded an opportunity to determine the
effect of IL-33/IL-33 receptor signaling on airway hyperreactivity
after viral infection, since we found alterations in reactivity even
with control antibody treatment (data not shown). In any case,
we observed attenuation of postviral increases in absolute values
for lung resistance at baseline and after methacholine challenge,
but no significant effect on fold change in baseline resistance after
methacholine challenge in Il1rl1–/– mice (Figure 3, G and H). These
results suggest that IL-33/IL-33 receptor signaling to IL-13 production does not fully control airway hyperreactivity and that additional factors may influence this response after viral infection. The
findings highlight again the relatively potent control of the IL-33–
to–IL-13 axis over airway mucus production after viral infection.
In the third approach, we determined the effect of IL-33 deficiency
on postviral response using homozygous IL-33 gene trap (Il33Gt/Gt)
mice, which were engineered with a LacZ reporter to disrupt the
IL-33 allele (37). In this case, we again found no difference in acute
illness in Il33Gt/Gt versus WT mice (Figure 4, A–C), but observed significant blockade of the expected development of chronic disease,
signified by IL-13 and mucus production and M2 differentiation
(Figure 4, D–F). Together with our previous work (11, 12), these 3
approaches (anti-IL1RL1 mAb, IL1RL1 deficiency, and IL-33 deficiency) served to demonstrate a specific role for IL-33/IL-33 receptor signaling in driving lung IL-13 and mucus production in the
postviral mouse model of chronic obstructive lung disease.
Consistent with a role for IL-33 production in IL-13–dependent
disease after viral infection, we found that delivery of IL-33 to
the mouse airway was also sufficient to cause IL-13 production
and consequent mucus overproduction (Supplemental Figure 2).
Administration of IL-25 also caused induction of Il13 and Muc5ac
gene expression, but blockade of IL-25/IL-25 receptor signaling
(accomplished using Il25–/– and Il17rb–/– mice as well as by anti–
IL-25 and anti-IL17RB mAb administration) had no significant
effect on airway inflammation, mucus overproduction, or Il13
and Muc5ac gene induction at SeV dpi 49 (Supplemental Figure
2). These results, together with the lack of induction of Il25 gene
expression in the postviral lung (Figure 1, A and B), indicate that
IL-25/IL-25 receptor signaling does not contribute significantly to
IL-13 and mucus production in the postviral mouse model. These
results contrast with the reported role of IL-25 in driving IL-13
production in ovalbumin and/or Aspergillus oryzae sensitizationchallenge models of allergic airway disease (17, 38).
IL-33–expressing epithelial cells in the mouse model. We also used 3
approaches to determine the cellular site for increased IL-33 expression in the postviral mouse model. In the first approach, FACS-based
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Figure 2
Effect of IL1RL1 blockade in the postviral mouse model. Mice were inoculated with SeV-UV or SeV, then treated as indicated with anti-IL1RL1
mAb or control IgG1 mAb (IgG) on dpi 12–49, and examined at dpi 49. (A) Representative photomicrographs of mouse lung sections for IL-13 and
MUC5AC immunostaining and PAS staining. Scale bars: 200 μm. (B) Lung levels of Il13, Clca3, and Muc5ac mRNA. (C) Levels of MUC5AC+
airway epithelial cells. (D). Lung levels of Arg1 and Chi3l3 mRNA. (E) Lung levels of Il33 and Il1rl1 mRNA. (B–E) Values represent mean ± SEM
(n = 7 per group, representative of 3 experiments). *P < 0.05 versus untreated SeV.
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Figure 3
Effect of IL1RL1 deficiency in the postviral mouse model. Il1rl1–/– and WT mice were inoculated with SeV or SeV-UV. (A) Body weight. (B) Lung
levels of SeV RNA at dpi 5. (C) Representative photomicrographs showing H&E staining of lung sections at dpi 5. (D) Representative photomicrographs showing PAS staining of lung sections at dpi 49. (E) Representative photomicrographs showing IL-13 and MUC5AC immunostaining
of lung sections at dpi 49. (F) Lung levels of Il13, Muc5ac, Arg1, and Il33 mRNA (n = 5–7 per group). *P < 0.05 versus corresponding WT.
(G and H) Airway reactivity to inhaled methacholine (MCh) at SeV dpi 49 (n = 15–21 mice per group). (G) Total lung resistance (RL) and fold change
from baseline were not significantly different by 2- and 3-way ANOVA. (H) Differences for lung resistance at baseline and after methacholine
(1.25 mg/ml). Scale bars: 200 μm.

analysis of lung cell populations was used to demonstrate that the
levels of Il33 mRNA were increased to the greatest extent in CD45–
lung cells from mice at SeV dpi 49, whether Il33 level was compared
across all cell populations (CD45–, CD45+, and CD45+F4/80+) or
within each individual cell population (Figure 5A and Supplemental
Figure 3). The levels of Il33 mRNA copies were 600- to 100-fold higher in the CD45– cell population compared with CD45+ hematopoietic cells, including CD45+F4/80+ lung macrophages, at SeV dpi 49.
Within the CD45– population, Il33 mRNA was found primarily in
cells expressing EpCAM (also known as CD326), consistent with an
epithelial (and perhaps progenitor/stem) cell origin (Supplemental
Figure 3 and refs. 39, 40). We also detected an increase in the levels of
Il33 mRNA in CD45+ cells, including CD45+F4/80+ macrophages, at

SeV dpi 1 and 3 as well as IAV dpi 1; however, the levels of Il33 mRNA
were still at least 40-fold higher in CD45– cells, even at these early
times after infection (Supplemental Figure 3).
In the second approach, we further localized the site for induction of IL-33 expression using in situ hybridization for Il33
mRNA. In this case, we again found predominant induction of
Il33 gene expression in epithelial cells at SeV dpi 49 (Figure 5B).
The most abundant Il33 mRNA signal was found in airway epithelial cells with morphology typical of serous cells (also known
as Clara cells). A trace signal was also detected in cells with alveolar type 2 cell morphology and was present with and without
SeV infection. In all cases, the Il33 mRNA signal was cytosolic, as
expected for mRNA localization.
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Figure 4
Effect of IL-33 deficiency in
the postviral mouse model.
Il33Gt/Gt and WT mice were
inoculated with SeV or
SeV-UV. (A) Body weight.
(B) Lung levels of SeV RNA
at dpi 5. (C) Representative
photomicrographs showing
H&E staining of lung sections at dpi 5. (D) Representative photomicrographs
showing PAS staining of
lung sections at dpi 49. (E)
Representative photomicrographs showing IL-13 and
MUC5AC immunostaining
of lung sections at dpi 49.
(F) Lung levels of Il13,
Muc5ac, Arg1, and Il1rl1
mRNA (n = 5–7 per group).
*P < 0.05 versus corresponding WT. Scale bars:
200 μm.

In the third approach, we used heterozygous IL-33 gene trap
(Il33Wt/Gt) mice, which express the LacZ reporter cassette under
the endogenous Il33 gene promoter (37) and manifested acute
and chronic responses to SeV infection similar to those of WT
mice, including development of mucus production and IL-13 and
MUC5AC immunostaining (Figure 5C). Il33Wt/Gt mice also showed
induction of Il33 gene expression (signified by β-gal reporter
expression) in a subset of cells with location and morphology typical of airway serous cells at SeV dpi 49, and these cells costained
with serous cell markers secretoglobin 1a1 (SCGB1A1) and especially SCGB3A1 (Figure 5D). SCGB1A1 staining was also present
at baseline conditions (SeV-UV dpi 49), but SCGB3A1 staining was
more pronounced at SeV dpi 49. These results were consistent with
whole genome expression microarray of lung tissue that showed
increased mRNA for airway serous cell genes (e.g., Scgb3a1 and
Cyp7b1) at SeV dpi 49 compared with SeV-UV infection (Figure 1A
3972

and Supplemental Table 1). We also detected IL-33/β-gal expression in a subset of cells with location and morphology typical of
alveolar type 2 cells that costained with the alveolar type 2 cell
marker surfactant protein C (SFTPC), but these signals were also
found at baseline, as noted previously (37).
We also detected KRT5+ basal cells in the distal airway and in the
parenchyma (Figure 5E). This cell population is normally restricted
to the trachea (36, 41), but is detectable after IAV infection in the
same location as that after SeV infection (42). This result was also
consistent with whole genome expression of lung tissue at SeV dpi 49
that showed significant increases in mRNA for basal cell genes (e.g.,
Krt5, Krt14, Krt15, Krt17, Aq3, Trp63, and Ngfr) (Figure 1A and Supplemental Table 1). However, IL-33/β-gal expression was not detected in
KRT5+ basal cells, MUC5AC+ mucous cells, α-tubulin+ ciliated cells,
or F4/80+ monocytes/macrophages (Figure 5E and Supplemental
Figure 4). IL-33/β-gal expression was no longer detectable in WT
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Figure 5
Localization of IL-33 expression to subsets of lung epithelial cells in the postviral mouse model. (A) Levels of Il33 mRNA from lung tissue preparation (Tissue Prep), lung cell preparation before FACS (Cell Prep), and the indicated cell populations purified by FACS from lungs obtained at dpi 49.
Values are representative of 3 experiments. (B) Representative photomicrographs showing in situ hybridization for Il33 mRNA at dpi 49. (C)
Representative photomicrographs showing PAS staining and IL-13 and MUC5AC immunostaining in Il33Wt/Gt lung sections at dpi 49. (D) Representative photomicrographs showing IL-33 immunostaining (detected with anti–β-gal antibody) and indicated cell type–specific costaining and
DAPI counterstaining in Il33Wt/Gt lung sections at dpi 49. (E) Representative photomicrographs for additional immunostaining using conditions in D.
Boxed regions in B–E are shown at higher magnification below (enlarged ×2). Scale bars: 200 μm (B and C); 100 μm (D and E).

mice (Supplemental Figure 4), thereby excluding the nonspecific
staining found for anti-mouse IL-33 antibodies (37). The present
approach also offers the advantage of detecting only IL-33 production, not IL-33 bound to its receptor on the target cell. Together, the
concerted approaches for IL-33 localization (i.e., PCR assay of FACSpurified cells, in situ hybridization, and IL-33 reporter mice) indicated that IL-33 expression in postviral mice with chronic obstructive lung disease is traceable to a newly induced subset of airway
serous cells marked especially by SCGB3A1 expression as well as a
constitutive subset of alveolar type 2 cells marked by SFTPC expres-

sion. Thus, IL-33 expression marks an airway serous cell population
linked previously to repair, renewal, and remodeling in the distal airway epithelium (34, 35, 43, 44) and an alveolar type 2 cell population
responsible for the same progenitor functions in the alveolar compartment (45, 46). The findings suggested that an IL-33–expressing
progenitor cell population might be a feature of chronic obstructive
lung disease, so we pursued this possibility in humans.
IL-33–expressing basal cells in COPD in vivo. To translate our findings
from the mouse model to humans, we used whole lung explants
from recipients undergoing lung transplantation for very severe
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Figure 6
Selective increase in IL-33–expressing airway epithelial cells in COPD. (A). Levels of IL33, IL25, and TSLP mRNA in non-COPD (n = 7) and COPD
(n = 15) lung tissues. (B) Levels of IL-33, determined by ELISA, using non-COPD (n = 16 samples from 9 subjects) versus COPD (n = 17 samples
from 11 subjects) lung lysates. (C) Levels of IL33 mRNA in lung cells before FACS (Pre-sort Cells) and the indicated cell populations purified
by FACS from COPD subjects (n = 4) using labeled anti-CD45 and anti-CD14 mAb. (D) Representative photomicrographs of sections of airway
epithelium immunostained for IL-33 with DAB (brown) reporter and counterstained with tartrazine (yellow). (E) Number of IL-33+ cell nuclei per
millimeter basement membrane in non-COPD (n = 6) versus COPD (n = 10) lung tissues. (F) Representative photomicrographs of non-COPD
and COPD airway epithelium sections immunostained for IL-33 with red (Alexa Fluor 594) reporter; costained for MUC5AC, SCGB1A1, or FOXJ1
with green (Alexa Fluor 488) reporter; and counterstained with DAPI (blue). (A, B, and E) Box represents 25th–75th percentile; line represents
median; “+” represents mean; whiskers represent range. (C) Bars represent mean ± SEM. P values were derived from unpaired Student’s t test,
but comparisons of medians were also made using Mann-Whitney U test with similar results. Scale bars: 100 μm.

(GOLD Stage IV) COPD (Supplemental Table 2), compared with
lungs from non-COPD donors, to assess expression of TSLP, IL-25,
and IL-33. We found significantly increased IL33 mRNA levels in
lung samples from COPD versus non-COPD subjects (Figure 6A).
To better address the relationship of increased IL-33 expression to
airway disease (particularly mucus production), we also examined
lung samples directed to airways based on CT imaging (47). In these
3974

airway-rich sections, we again found a significant increase in IL33
mRNA in COPD versus non-COPD subjects as well as increased
levels of IL13, IL13RA1, and MUC5AC mRNA (Supplemental Figure 5), consistent with our previous observations in smaller groups
of subjects (11, 13). Moreover, IL33 mRNA levels correlated with
MUC5AC and IL13RA1 mRNA levels across the group of COPD and
non-COPD lung samples (Supplemental Figure 5). We did not find
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Figure 7
Localization of IL-33 expression
to a subset of airway basal cells
in COPD. (A) Levels of KRT5,
KRT14, and TRP63 mRNA in
non-COPD (n = 18) and COPD
(n = 21) lungs. (B) Representative photomicrographs of nonCOPD and COPD airway epithelium sections immunostained
for IL-33; costained for KRT5,
KRT14, TRP63, or SCGB3A1;
and counterstained with DAPI.
Boxed regions are shown at higher magnification at right (enlarged
×4). Scale bars: 100 μm.

a correlation of IL13 with expression of IL33, IL13RA1, or MUC5AC,
perhaps a reflection of the relatively transient and low-level production of cytokines (such as IL-13) versus more stable and higher-level
expression of trigger, receptor, and responder components (such
as IL-33, IL-13 receptor, and MUC5AC) of the cytokine signaling
pathway. Although there was some degree of heterogeneity among
individual patients, we found no significant difference in either
IL25 or TSLP mRNA levels in COPD versus non-COPD subjects
(Figure 6A). The increase in lung IL33 mRNA levels was accompanied by a significant increase in IL-33 protein levels in lung samples
from COPD versus non-COPD subjects (Figure 6B).
We next traced the cellular source of increased IL-33 production
in the lungs of COPD subjects. Analysis of FACS-purified lung cell
populations indicated that the primary source of IL33 mRNA production in COPD was CD45– nonhematopoietic cells (Figure 6C

and Supplemental Figure 6). In concert with this finding, IL-33
immunostaining was most intense in airway basal cells present
in regions of epithelial hyperplasia and mucous cell remodeling
with and without associated bronchial-associated lymphoid tissue
(BALT) (Figure 6D and Supplemental Figure 6) and was characterized by an increased number of IL-33+ airway epithelial cells in
samples from COPD versus non-COPD subjects (Figure 6E). These
findings were consistent with detection of increased IL33 mRNA in
airway-containing samples from COPD versus non-COPD subjects.
We found no detectable IL-33 staining in more differentiated airway epithelial cells, i.e., MUC5AC+ mucous cells, SCGB1A1+ serous
cells, or FOXJ1+ ciliated cells, in non-COPD or COPD subjects
(Figure 6F). We did detect IL-33 immunostaining of endothelial
cells of the lung microvasculature along with scattered cells in the
interstitium, which in both cases was again localized to the nucleus.
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Figure 8
Basal cell capacity for tracheobronchosphere formation and IL-33 release in COPD. (A) Representative photomicrographs of hTECs isolated
from COPD subjects, cultured in 2D submerged conditions for 5 days, and immunostained for IL-33 and TRP63 and counterstained with DAPI.
(B) IL-33 levels in cell lysates for non-COPD and COPD subjects (n = 3 per group) as in A. (C and D) Flow cytometric analysis of hTECs cultured
from COPD and non-COPD subjects (n = 3 per group) and then permeabilized and stained for IL-33, ITGA6, and NGFR along with unstained
non-COPD control. (C) Representative cytograms. FL1, autofluorescence signal; FSc, forward scatter. Values indicate percent of cells within the
designated gate. (D) Histograms. (E) Representative photomicrographs showing IL-33 and ITGA6 immunostaining as in A. (F) Representative
photomicrographs of tracheobronchospheres in 3D culture using phase contrast and fluorescent microscopy for immunostaining for ablumenal/
basal KRT14 and lumenal/apical KRT8. (G) Quantitation of tracheobronchosphere formation for basal cells with and without FACS purification
from non-COPD (n = 3) and COPD (n = 5) subjects, using sorting and culture conditions as in C and F. (H) Levels of IL-33 released from hTECs
isolated from a COPD and a non-COPD subject, cultured submerged for 5 days, and then incubated with ATP for the indicated time periods.
Results are representative of 3–5 subjects. *P < 0.05 versus PBS at 0 h, 2-way ANOVA. Scale bars: 25 μm (A and E); 100 μm (F).
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Figure 9
IL-33/IL-13 immune axis in chronic obstructive lung disease. Respiratory viral infection leads to an increase
in lung epithelial progenitor cells (airway basal cells in
humans, and perhaps airway serous cells and alveolar
type 2 cells in mice) that are programmed for increased
IL-33 expression. Subsequent epithelial danger signals
stimulate ATP-regulated release of IL-33 that acts on
immune cells in the lung, e.g., CD4+ Th2 cells, innate
lymphoid cells (ILC), and semi-invariant NKT cells
with interacting monocytes and macrophages (Mono)
to stimulate IL-13 production and consequent airway
mucous cell and mucus formation.

The increase in IL-33–expressing airway basal cells was accompanied by significant increases in expression of conventional basal
cell genes (i.e., KRT5, KRT14, and TRP63) in the lungs of COPD
versus non-COPD subjects (Figure 7A). Moreover, IL-33 expression was localized to a subset of KRT5+, KRT14+, and TRP63+ airway basal cells, again particularly prominent in areas of epithelial
hyperplasia and mucous cell remodeling in COPD (Figure 7B).
IL-33 did not overlap completely with KRT5, KRT13, or TRP63
immunostaining, which suggests that IL-33–expressing cells represent a distinct airway basal cell niche. We did not detect IL-33
immunostaining in SCGB3A1+ airway serous cells (in contrast to
the mouse model) or in alveolar or tissue macrophages (Figure 7B
and data not shown). Based on the role of TRP63 in suppression
of apoptosis and prolongation of epithelial cell survival (48), similar to the case for EpCAM (40), our findings again suggested that
IL-33 expression may mark a progenitor cell population.
IL-33–expressing basal progenitor cells in culture. Given the tools
available for analysis of lung progenitor cells, we next examined
whether the IL-33 expression program continues ex vivo in basal
cells isolated from COPD and non-COPD subjects. We used whole
lung explants for blunt dissection of airways and then isolation
and culture of human tracheobronchial epithelial cells (hTECs)
under submerged conditions. These conditions prevented epithelial cell differentiation and thereby preserved airway basal cells,
including the IL-33+TRP63+ subset (Figure 8A). We found that, in
contrast to submerged culture conditions, IL33 mRNA was 150fold decreased and IL-33 protein was undetectable with cell differentiation in air-liquid interface conditions (data not shown).
Under submerged culture conditions, we also found that levels of
IL-33 expression were significantly increased in basal cells from
COPD versus non-COPD subjects even after 5 days in culture
(Figure 8B). We then subjected hTECs from submerged cultures to
intracellular staining for IL-33 along with detection of cell surface
markers that are selective for airway basal cells (i.e., nerve growth
factor receptor [NGFR] and integrin α6 [ITGA6]) (36). This strategy
revealed an association of IL-33 expression with an ITGA6hiNGFRlo
subpopulation of basal cells in both COPD and non-COPD subjects (Figure 8C), again with increased levels of IL-33 expression in
COPD versus non-COPD cells (Figure 8D).
Given the conventional role of basal cells as epithelial progenitors
in human airways (36, 42) as well as the association of IL-33 expression with typically progenitor cell populations in the mouse model,
we next checked for progenitor potential in basal cells isolated from

COPD and non-COPD subjects. We found that IL-33+ basal cells
placed into an enriched 3D Matrigel culture system were fully capable of forming structures with fidelity to original airway morphology (designated tracheobronchospheres). After culture of these tracheobronchospheres under differentiation-promoting conditions,
phase-contrast microscopy and video microscopy revealed proper
ciliary formation and movement (Figure 8F and Supplemental
Video 1), and immunofluorescence microscopy showed ablumenal
KRT14 and lumenal KRT8 expression, as expected for differentiated airway structure (36). Moreover, we observed a significantly
increased efficiency of sphere formation from cultures that were
enriched for IL-33–expressing (ITGA6hiNGFRlo) cells (Figure 8G).
Increased sphere formation was also found for cells obtained from
COPD versus non-COPD subjects (Figure 8G). These results provide evidence of a progenitor subset of airway basal cells that is
marked by IL-33 expression and is increased in COPD.
Our results from the postviral mouse model also indicated that
IL-33 must reach the extracellular space and bind to its receptor for
the development of lung disease (since disease was blocked using
anti-IL1RL1 mAb and by loss of IL1RL1). We therefore examined
the capacity for IL-33 release from basal cells, in light of previous
observations that extracellular ATP may act as a danger signal to
trigger IL-33 release by activation of purinergic receptor P2Y 2R
signaling (49). Consistent with this concept, direct administration
of ATP caused a significant increase in IL-33 release in basal cells
cultured from both COPD and non-COPD subjects (Figure 8H).
Under these conditions, IL-33 was detected exclusively in the apical medium and was found to accumulate at increasing levels over
1–3 days. We found no significant difference in cell morphology or
LDH release in ATP- versus PBS-treated COPD or non-COPD subjects (Supplemental Figure 7), consistent with a previous report of
noncytotoxic release of IL-33 (49). These data implicate a regulated
secretory process by which IL-33 release is directed under conditions of cellular stress. Taken together, these findings indicate that
a subset of the airway basal cells is programmed for IL-33 expression and release and that an increase in this cell population can
thereby serve as a renewable source of increased IL-33, with the possible downstream consequence of IL-13–dependent lung disease.
Discussion
It has been difficult to understand how an acute infection might
lead to a chronic inflammatory disease. We gained substantial
insight into this process with studies of viral infection in mice
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aimed at modeling the initiation, exacerbation, and progression
of chronic obstructive lung diseases such as COPD. In our mouse
model of this disease process, we uncovered an innate immune axis
involving semi-invariant NKT cells and M2 monocytes and macrophages that drives IL-13 production and consequent airway mucus
production and hyperreactivity that are characteristic of chronic
obstructive lung disease in humans (10–12, 44, 50). We recognized,
however, that there must be upstream factors that more directly
link acute viral infection with chronic activation of immune effector cells. In the present study, we assessed the factors best known to
regulate IL-13 production, i.e., IL-25, TSLP, and IL-33, and showed
that IL-33 was a primary influence on the innate immune axis
that drives IL-13–dependent lung disease. Our present findings
suggested a primary role for IL-33 in experimental (mouse) and
clinical (human) forms of chronic lung disease. (a) In the postviral
mouse model, IL-33 expression was selectively induced relative to
IL-25 and TSLP, and IL-33/IL-33 receptor signaling was required
for chronic increases in IL-13 and airway mucus production. (b)
In this model, IL-33 expression was particularly localized to airway serous cells and alveolar type 2 cells, which suggests that a
progenitor population might account for long-term IL-33 expression and consequent IL-13–dependent disease. (c) In humans with
very severe COPD, IL-33 expression was also selectively increased
in lung tissue and was significantly associated with an IL-13 and
mucin gene signature, in concert with excess airway mucus production. (d) In these subjects as well as in control subjects, IL-33
expression was particularly localized to nuclei in a subset of airway
basal cells that were increased in COPD and are also conventionally
linked to progenitor function. (e) In an ex vivo analysis of this basal
cell subset, increased nuclear expression of IL-33 was preserved in
basal cells cultured from COPD subjects and marked a cell population with increased pluripotency and ATP-regulated release of
IL-33. Together, these results suggest a new scheme for an IL-33/
IL-13 immune axis in which an epithelial progenitor cell population can store and release IL-33 to drive downstream IL-13 and
consequent airway mucus production that is typical of COPD and
perhaps other IL-13–dependent diseases (Figure 9).
An intriguing aspect of our findings is the potential role of an
inducible progenitor population in the development of chronic
inflammatory disease. Full development of this concept is limited
by our present understanding of the progenitor populations in
lung injury and repair, including the renewal process that occurs
after viral infection. In other mouse models of this process (with
and without cell lineage tracking), airway serous cells in the distal
airway and alveolar type 2 cells in the alveolar space are generally
regarded as progenitors (34, 35, 45, 46), but whether they can be
reprogrammed (e.g., by viral infection) to drive chronic disease represents a new paradigm for pathogenesis. Airway and parenchymal
basal cells (marked by KRT5 expression) may develop after IAV and
SeV infection (ref. 42 and the present study), but specific diseaseproducing functions of this cell population remain uncertain. For
example, we did not find IL-33 expression in this basal cell population in the postviral mouse model of chronic obstructive lung
disease. Conversely, it is also generally accepted that airway basal
cells are linked to progenitor function in human lungs (36, 41);
here, we confirmed this proposal and established a further connection to regulated IL-33 expression and release in human lung
disease. Since IL-33 expression did not fully coincide with that of
other basal cell markers, the IL-33–expressing basal cells (as well
as the IL-33+ serous cells in mice) appear to represent a special3978

ized airway cell niche. The basis for how such a population might
develop still needs to be defined, but our present results suggest
that an epigenetic change in this population, perhaps a result of
viral reprogramming, might allow for increased abundance of a
progenitor subset marked by IL-33 expression.
In pursuing this question, it may be useful to recognize that the
progenitor cell program can be relatively inefficient when assessed
by tracheobronchosphere formation (e.g., 18 spheres per 3,000
cells seeded, or approximately 0.6% in samples from COPD subjects), as reported previously (36, 51, 52). However, sphere-forming
efficiency is likely decreased by several of the present experimental
conditions, e.g., cellular stress during isolation, cell seeding at low
density, and lack of additional supplementation with growth factors and/or fibroblast feeder layers. Further work will be needed to
determine the precise relationship of progenitor cell function to
IL-33 expression and whether IL-33 serves as a marker or a driver
of self renewal and/or mucous cell differentiation. Nonetheless,
the increase in sphere-forming efficiency in IL-33–enriched populations in samples from COPD and non-COPD subjects suggests
at least some degree of linkage between IL33 gene expression and
progenitor cell function.
The progenitor nature of an IL-33–expressing, ATP-responsive
cell population could explain the acquired susceptibility to excess
mucus production typical of airway disease, but this response may
also provide an advantage to the host. Others previously reported
a protective role for IL-33 signaling after high-dose intracerebral
lymphocytic choriomeningitis virus (LCMV) infection, but found
no change in viral clearance at lower inoculum (53), similar to
our present results. However, as noted above, it may be useful to
consider the chronic condition: long-term IL-33 production may
provide for increased airway mucous cells that may be less susceptible to viral infection (54) and facilitate the immune response
(55). Similarly, mucus production may facilitate export of noxious
materials via cough and/or mucociliary clearance. It is possible
that these mucous cell benefits are lost if other environmental
stimuli, such as tobacco smoke or allergen, are introduced in conjunction with viral infection to drive excessive mucus production.
This issue will require further studies of viral infection in combination with other risk factors for chronic obstructive lung disease.
Our present findings also reinforce and expand the unusual
role of IL-33 as a secreted cytokine despite nuclear expression. In
the postviral mouse model, extracellular IL-33 acts in a paracrine
manner by interacting with its cognate receptor to drive IL-13 production and consequent M2 differentiation and mucus overproduction. In this case, administration of anti-IL1RL1 or engineered
deficiency of IL1RL1 blocks these effects (56, 57). In our studies of
human lung cells, available tools permitted localization of IL-33
to the nuclei of airway basal cells in vivo and in vitro. This situation was consistent with the proposal that IL-33 is constitutively
expressed at a high level in basal cells of other epithelial barriers
(e.g., skin and genitourinary tract) and can be released with cellular
stress (37, 49). Whether release of IL-33 for activation of its receptor is regulated by cell turnover or by alarm signals from external
stimuli likely depends on the stimulation conditions, but at least
in the mouse model, long-term induction and action of IL-33
appears to continue without any obvious stimulus for cell death or
damage. Nonetheless, our results using basal cells indicated that
further cellular stress and consequent ATP release could stimulate even higher levels of IL-13 expression, M2 differentiation, and
mucus production. These characteristics of IL-33 processing and
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action would fit with our observations that it was a more robust
marker of chronic lung disease, even at baseline, compared with its
downstream readouts.
Our results also help to clarify the cellular target of IL-33
action. Others have proposed a role for IL-33 derived primarily
from alveolar macrophages in the development of airway hyperreactivity after IAV infection (24). This conclusion was based on
immunostaining with anti-mouse IL-33 antibody (24), which
has been problematic, as noted above and in previous reports
(37). In contrast, our work and that of by others showed that
IL-33 expression was often localized to nonhematopoietic cells
(37, 53, 58, 59, and the present study). Indeed, our findings fit
best with immune cells being a target, rather than a source, of
IL-33. The precise and quantitative identification of the immune
cell populations that respond to IL-33 with production of IL-13
during postviral disease in mice or chronic obstructive lung disease in humans is still being fully defined. Our initial study of
this issue pointed to a predominant functional role for NKT
cells and monocytes/macrophages (11), but we also recognized
that IL-13–producing innate lymphoid cells were also activated
in the postviral mouse model (60, 61). A comprehensive analysis of IL-13–producing cells in the mouse model and in human
subjects — and, ultimately, selective blockade of these populations — will be required to fully define this issue. It remains possible that IL-33 has additional effects on airway epithelial (and
endothelial) cells in the lung, as described previously (62, 63),
but the functional consequences of this action under healthy or
disease conditions remain uncertain.
Others have also proposed a role for IL-25 and TSLP in the development of chronic obstructive lung disease due to asthma (26, 27),
and, to a much more limited extent, in COPD (25). We did not
detect significant differences in lung levels of IL25 or TSLP mRNA
in our cohort of COPD patients with very severe disease compared
with non-COPD controls, but we cannot exclude a role for these
cytokines in controlling IL-13 production or some other aspect
of lung disease. In fact, we did observe upregulation of IL-25 and
TSLP expression in the lungs of some subjects with severe COPD,
but not all. Given the potent action of IL-25 on induction of IL-13
expression, at least in mice, it is possible that IL-25 (with or without synergy with IL-33) could contribute to overproduction of
mucus in some individuals. In the case of TSLP, however, we found
only low levels of expression in COPD and a decrease in expression
after viral infection in mice. While further studies of TSLP function need to be done, our present data suggest that the contributions of TSLP to obstructive lung disease may not derive from its
direct actions in the lung. TSLP is reported to have potent effects
in the skin that may lead to allergic asthma (64), but there is no
connection as yet to nonallergic lung disease.
Similarly, population studies indicate an association of SNPs
near IL1RL1 on chromosome 2 and IL33 on chromosome 9 with
the development of asthma (65–67), but to our knowledge, no
similar associations have been reported for COPD thus far (68).
Moreover, the present results suggest that environmental agents
(i.e., viral infection) may alter IL-33 expression, making it likely
that epigenetic approaches may be more informative than studies
of gene sequence in identifying a basis for COPD-related differences in airway epithelial cells. Similarly, we do not yet understand
the genetic or acquired regulatory events that control IL33 gene
expression or IL-13 protein processing in progenitor cells. There
is a report of Notch dependency for IL-33 expression in vascular

endothelial cells (69), but whether this system is involved in IL-33
expression in airway epithelial cells or has any role in inflammatory lung disease still needs to be defined.
In summary, we used a mouse model of chronic obstructive lung
disease to guide our understanding of the immune pathways that
contribute to similar disease due to COPD in humans. In both the
mouse model and in COPD subjects, we detected induction of an
IL-33–expressing epithelial cell population with progenitor characteristics that could account for long-term activation of an innate
IL-13 immune axis. The consequent accumulation of inflammatory airway mucus is critical to the morbidity and mortality of
chronic lower respiratory disease (31, 32, 70), which now ranks as
the third most common cause of death in the United States and
the fifth worldwide (71, 72). The relationship of the epithelial cell
IL-33–to–immune cell IL-13 pathway with other risk factors for
COPD, such as tobacco smoking, still needs to be defined. Nonetheless, our results suggest that viral infection is a suitable candidate to drive acute exacerbations with long-term consequences
for progression and consolidation of chronic obstructive lung
disease. In fact, viral infection appears significantly more potent
than smoke exposure as a stimulus of airway inflammatory disease
under experimental conditions (73, 74). This issue will be better
settled as key immune components, e.g., IL-33 and IL-13, are effectively blocked in patients with chronic lung disease. The present
findings lay the groundwork for this therapeutic strategy and provide a rational basis for how acute infectious agents (such as common respiratory viruses) can reprogram long-term progenitor cells
(such as airway basal cells) to cause chronic inflammatory disease.
Methods
Mouse generation and treatment. Male mice (6–12 weeks of age) on a C57BL/6
background were used for all experiments. WT C57BL/6J mice were
obtained from Jackson Laboratories. Il25–/– mice (75) were provided by A.
McKenzie (Cambridge, England) and backcrossed to C57BL/6 for a total
of 10 generations. Il17rb–/– mice on a C57BL/6 background as well as antimouse IL-25 (clone M819) and IL17RB (clone M735) mAbs (76) were provided by A. Budelsky (Amgen, Seattle, Washington, USA). Il1rl1–/– mice
(56, 57) were obtained from P. Bryce (Northwestern University, Chicago,
Illinois, USA). Il33Gt/Gt mice were generated with insertion of a gene trap
cassette containing the LacZ (bgeo) reporter into intron 1 of the Il33 locus,
as described previously (37). Anti-mouse IL1RL1 (clone M955) and control IgG1 (clone 4D2) mAbs were provided by D. Smith (Amgen, Seattle,
Washington, USA). Mice were inoculated with either SeV (1 × 105 pfu), an
equivalent amount of SeV-UV, or PBS, as described previously (11). Inoculation with SeV-UV and PBS gave identical results and were therefore treated
as equivalent control conditions. For mAb blocking experiments, mice
were injected at weekly intervals beginning at dpi 12 with anti–IL-25 mAb
(500 μg/wk), anti-IL17RB mAb (500 μg/wk), anti-IL1RL1 mAb (200 μg/wk),
or an equivalent amount of control Ig given intraperitoneally, as described
previously (76, 77). For cytokine administration, recombinant mouse IL-25
and IL-33 (R&D Systems) were reconstituted per the manufacturer’s recommendations, diluted in PBS, and administered intranasally.
Gene expression microarray. Gene expression analysis was performed using
Illumina Mouse-WG6 v2 BeadChips (Illumina). Total RNA was isolated
from lung homogenates using the RNEasy kit (Qiagen) and was amplified and biotinylated using the Illumina TotalPrep Kit (Ambion). Treatment and conditions were randomized across BeadChip slides to avoid
confounding (78). Hybridization and scanning of BeadChip arrays was
performed with BeadStudio 3.0 software (Illumina). Microarray normalization and analysis was performed with Bioconductor packages in the
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R programming environment (79). Raw bead-level intensity data import
and background correction was performed using the beadarray package
(80). Each Mouse-WG6-v2 BeadChip array consists of 2 strips, which must
be treated separately through bead-type summarization due to potential
variation in the data from the 2 strips (81). For each strip, low-level analysis and quality control was performed using the beadarray package (82).
The BASH algorithm was applied to mask beads affected by large spatial
artifacts (83), followed by bead-type summarization, including outlier
bead removal (82). Summarized data were log2 transformed, then quantile normalized (84). Bead types whose expression was not detected on any
strip in the experiment (detection P > 0.05) were removed. Data from the
2 independently processed strips per array were then merged. Differential
expression was assessed using linear models and empirical Bayes moderated F statistics, as implemented in the LIMMA package (85). To improve
interpretation (86), bead types were annotated using annotations from
Illumina (87), ReMOAT (88), AILUN (89), AceView (90), and Ensembl
(91). Differences in gene expression were considered significant if P < 0.05
after adjustment for multiple testing (92), limiting the false discovery rate
to <5%. Visualization and plotting was performed using DecisionSite for
Functional Genomics (TIBCO Spotfire). Microarray data were deposited in
GEO (accession no. GSE49603).
Real-time PCR assay. RNA was purified from lung homogenates using
TRIzol (Invitrogen) and converted to cDNA using a High-Capacity cDNA
Archive kit (Applied Biosystems). Target mRNA was quantified by realtime PCR assay using specific fluorogenic probes and primer sets and the
Fast Universal PCR Master Mix system (Applied Biosystems). See Supplemental Table 3 for primer-probe sets for human and mouse mRNA targets.
All probes were designed to span introns and did not react with genomic
DNA. Samples were assayed with the 7300HT or 7500 Fast Real-Time PCR
System and analyzed using Fast System Software (Applied Biosystems). For
human tissues, Ct values were normalized to GAPDH mRNA and expressed
as fold change relative to the mean Ct value for the non-COPD control
samples using the ΔΔCt method (93). For mice, cDNA mRNA copy numbers were corrected for Gapdh mRNA and expressed as fold change relative
to the mean expression level in control mice.
Immunohistochemistry. Tissues were fixed with 10% formalin, embedded in
paraffin, cut into 5-μm sections, and adhered to charged slides. Sections
were deparaffinized in Fisherbrand CitroSolv (Fisher), hydrated, and treated with heat-activated antigen unmasking solution (Vector Laboratories).
Immunostaining was performed using primary antibodies (Supplemental
Table 4) followed by labeled secondary antibodies. Antibody binding was
detected using diaminobenzidine (DAB) with hematoxylin (in mouse) or
tartrazine (in human) counterstain for brightfield microscopy, or with
tyramide-based signal amplification using Alexa Fluor 488 or Alexa Fluor
594 fluorochromes (Invitrogen) for immunofluorescence microscopy. In
mouse lung tissue, the number of MUC5AC+ cells was quantified using
ImageJ software (NIH). In human tissues, the number of IL-33+ cells was
quantified using Nanozoomer (Hamamatsu) virtual microscopy and Viziomorph software (Visiopharm).
FACS analysis. For immune cell experiments, single-cell suspensions were
generated from minced lung tissue that was subjected to collagenase (Liberase Blendzyme III, Roche), hyaluronidase (Sigma-Aldrich), and DNAse I
(grade II, Roche) digestion for 45 minutes at 37°C. After FcR blockade,
lung cell suspensions were incubated with labeled antibodies and sorted
using a Moflo (DAKO-Cytomation) high-speed cell sorter. Nonviable
cells were excluded from analysis by 7-AAD staining. Mouse cells were
immunostained with PE-Cy7–conjugated anti-mouse F4/80 (Ebioscience) and FITC-Cy5.5–conjugated anti-mouse CD45 (Ebioscience), and
human cells were immunostained with APC-conjugated anti-human
CD14 (BD Biosciences) and biotin-conjugated anti-human CD45 (BD
3980

Biosciences). For hTEC experiments, cells were detached from inserts with
trypsin/EDTA solution and immunostained using anti-NGFR rabbit Ab
(Abcam) detected with APC-conjugated anti-rabbit Ab (Santa Cruz) and
PE-Cy7–conjugated anti-ITGA6 rat Ab (Ebioscience). For IL-33 costaining,
cells were then fixed with 4% paraformaldehyde, permeabilized with 0.5%
IGEPAL (Sigma-Aldrich), immunostained with biotinylated anti–IL-33
mAb (clone Nessy-1, Enzo Life Biosciences) and PE-labeled streptavidin
(BD Pharmingen), and costained using anti-NGFR rabbit Ab (Abcam)
detected with APC-conjugated anti-rabbit Ab (Santa Cruz) and PE-Cy7–
conjugated anti-ITGA6 rat Ab (Ebioscience). Flow cytometry results were
plotted and analyzed using FlowJo software (TreeStar).
In situ hybridization. Tissue sections were pretreated to block nonspecific
binding and then hybridized overnight with digoxygenin-labeled antisense
RNA probe for Il33 mRNA, as described previously (94). After stringent
washing and RNase treatment, Il33 mRNA was detected using an antibodylinked alkaline phosphatase reaction with BM purple chromophore (Roche
Diagnostics), and sections were counterstained with nuclear fast red.
Cytokine ELISA. ELISA for human and mouse IL-33 was performed using
IL-33 Duosets (R&D Systems) according to the manufacturer’s protocol.
For mouse and human sample preparation, lung tissues were homogenized in T-PER reagent containing HALT protease inhibitors (Pierce), and
the tissue lysate was diluted (2 μl in 100 μl of 1% BSA) and incubated on
plates for 2 hours at 25°C. Plates were washed, then incubated with biotinylated detection antibody followed by streptavidin HRP. Antibody binding was detected with TMB substrate (KPL), quenched with HCl (1 M), and
assayed by absorbance at 450 nm. IL-33 level was quantified on a 7-point
standard curve and normalized to total protein in the sample. For mouse
samples, lung tissues were homogenized in T-PER reagent (Pierce) with the
mammalian protease inhibitor cocktail (Sigma-Aldrich), and ELISA was
performed as described above.
Human lung samples. Clinical samples were obtained from lung explants
harvested at the time of lung transplantation from COPD recipients (n = 35)
with very severe disease (GOLD Stage IV) during the period from 2005 to
2012 at Barnes-Jewish Hospital (St. Louis, Missouri, USA). Control samples
were obtained from non-COPD donors (n = 18) using both lung explants
that were otherwise not useable for transplantation and excess lung tissue
that was resected for downsizing. For the first analysis of gene expression,
lung explant samples were obtained from a group of COPD recipients
(n = 7) and non-COPD donors (n = 15) without airway localization. For the
second analysis of gene expression, samples were obtained from a group of
COPD recipients (n = 16) and non-COPD donors (n = 7), using CT imaging
of the lung explant to ensure inclusion of airway tissue, as described previously (47). Each analysis consisted of samples from COPD recipients with
the same clinical characteristics (Supplemental Table 2).
Airway epithelial cell culture. Primary culture hTECs were established
from tracheobronchial specimens of COPD recipients and non-COPD
donors using 2D submerged and air-liquid interface cultures as well as
3D sphere culture conditions, as described previously (36, 95). For the
present experiments, cells were grown in UNC BEGM without retinoic
acid (RA) or ALI medium (96) in 12-mm Transwell permeable support
plates (Corning Life Sciences). For 2D cultures, cells in submerged format were seeded at 20,000 cells/well, grown to confluence (3–5 days) in
BEGM (upper and lower chambers), and used for study. The air-liquid
interface condition was established by removing medium from the upper
chamber and changing the medium in the lower compartment to UNC
ALI medium supplemented with RA (50 nM), then culturing cells for an
additional 21 days. For IL-33 release experiments in submerged 2D cultures, cells were incubated with ATP (10 μM) from Cytoskeleton or PBS
vehicle, and IL-33 level was determined by ELISA and LDH level by activity assay (Sigma-Aldrich). For 3D tracheobronchosphere cultures estab-
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lished on pre- and post-sort (IL-33–enriched) populations, cells were
resuspended in BEGM, mixed 1:1 with growth factor–reduced Matrigel
(BD Biosciences), and plated at 3 × 103 cells per 100 μl in Transwells.
After 7 days, medium in lower chamber was changed from BEGM to UNC
ALI supplemented with RA, and spheres were cultured for 30 days. Differentiated spheres were counted and were assessed for ciliary beating
using the SAVA system. Spheres were harvested from Matrigel using cell
recovery solution (BD Biosciences) and embedded in OCT (Tissue-Tek)
for frozen sectioning and immunostaining.
Statistics. Unless otherwise stated, all data are presented as mean ± SEM,
and 2-tailed unpaired Student’s t test was used to assess statistical significance between means. In all cases, a P value less than 0.05 was considered
significant. All values are representative of at least 3 experiments.
Study approval. All animal experiments were performed using protocols
approved by the Washington University Animal Studies Committee. All
human studies were conducted with protocols approved by the Washington University Institutional Review Board, and subjects provided informed
consent prior to their participation in the study.
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